secwatch.observer — SEC 8-K summary
======================================

Issuer:     FOXO TECHNOLOGIES INC. (FOXO)
CIK:        0001812360
Form:       8-K
Filed at:   2026-07-29T12:35:11+00:00
Accession:  0001493152-26-035110
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FOXO subsidiary Vector BioSource to acquire four blood collection centers from Grifols
--------------------------------------------------------------------------------

- Acquisition structured as asset purchase with upfront cash and potential earnout based on EBITDA targets in 2026-2028.
- Expected to add over $10M in net revenues in 12 months post-closing from sale of whole blood, serum, and other bio-samples.
- Closing anticipated in Q3 or Q4 2026, subject to FDA licensure and other regulatory authorizations.
- Acquisition intended to provide proprietary bio-products and expand Vector's accessible market via new FDA licensure.
- Vector CEO cites milestone in evolving from biospecimen sourcing to integrated biospecimen solutions company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812360/000149315226035110/0001493152-26-035110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812360/000149315226035110/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-035110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer